These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21570531)
1. Peripheral artery disease, biomarkers, and darapladib. Berger JS; Ballantyne CM; Davidson MH; Johnson JL; Tarka EA; Lawrence D; Trivedi T; Zalewski A; Mohler ER Am Heart J; 2011 May; 161(5):972-8. PubMed ID: 21570531 [TBL] [Abstract][Full Text] [Related]
2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
3. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A; Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397 [TBL] [Abstract][Full Text] [Related]
4. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis. Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282 [TBL] [Abstract][Full Text] [Related]
5. Chronic inhibition of lipoprotein-associated phospholipase A Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475 [TBL] [Abstract][Full Text] [Related]
7. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by inhibition of lipoprotein-associated phospholipase A2. Zhang H; Zhang JY; Sun TW; Shen DL; He F; Dang YH; Li L Clin Invest Med; 2013 Feb; 36(1):E32-41. PubMed ID: 23374598 [TBL] [Abstract][Full Text] [Related]
8. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Daida H; Iwase T; Yagi S; Ando H; Nakajima H Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604 [TBL] [Abstract][Full Text] [Related]
9. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559 [TBL] [Abstract][Full Text] [Related]
10. Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial. Johnson JL; Shi Y; Snipes R; Janmohamed S; Rolfe TE; Davis B; Postle A; Macphee CH PLoS One; 2014; 9(2):e89034. PubMed ID: 24586490 [TBL] [Abstract][Full Text] [Related]
12. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis. Heriansyah T; Nafisatuzzamrudah N; Aini FN; Ridwan M; Primardhika RF; Wijayanti M; Bekti RS; Wihastuti TA Cardiovasc Hematol Agents Med Chem; 2018; 16(2):114-119. PubMed ID: 30394217 [TBL] [Abstract][Full Text] [Related]
19. Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial. Hu C; Tompson D; Magee M; Chen Q; Liu YM; Zhu W; Zhao H; Gross AS; Liu Y PLoS One; 2015; 10(10):e0139862. PubMed ID: 26465780 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. Wang WY; Zhang J; Wu WY; Li J; Ma YL; Chen WH; Yan H; Wang K; Xu WW; Shen JH; Wang YP PLoS One; 2011; 6(8):e23425. PubMed ID: 21909350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]